Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core

Bioorg Med Chem Lett. 2019 Mar 15;29(6):836-838. doi: 10.1016/j.bmcl.2019.01.018. Epub 2019 Jan 21.

Abstract

Starting from the recently launched FLT3/AXL multi-targeted inhibitor Gilteritinib (5), we conducted a side-chain ring closure medicinal chemistry approach leading to the identification of compound 15c as a highly potent AXL inhibitor in the biochemical and cellular anti-proliferative assays, with IC50 values of 1.2 and 0.3 nM, respectively. Compared with the reference compound 5, our new discovered AXL inhibitor 15c is more potent in both assays.

Keywords: AXL Kinase; Cancer; Pyrazine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aniline Compounds / chemistry
  • Aniline Compounds / pharmacology
  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology
  • Benzazepines / chemical synthesis
  • Benzazepines / pharmacokinetics
  • Benzazepines / pharmacology*
  • Cell Line, Tumor
  • Drug Discovery
  • Mice
  • Molecular Structure
  • Protein Kinase Inhibitors / chemical synthesis
  • Protein Kinase Inhibitors / pharmacokinetics
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrazines / chemical synthesis
  • Pyrazines / chemistry
  • Pyrazines / pharmacokinetics
  • Pyrazines / pharmacology*
  • Rats, Sprague-Dawley
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

  • Aniline Compounds
  • Antineoplastic Agents
  • Benzazepines
  • Protein Kinase Inhibitors
  • Pyrazines
  • gilteritinib
  • Axl protein, rat
  • Receptor Protein-Tyrosine Kinases